Glucagonomas – Characteristics and treatment options based on a French multicenter cohort study

#3656

Introduction: Glucagonoma is a rare functional pancreatic neuroendocrine tumor (pNET).

Aim(s): This study aimed to provide real-life data on the diagnostic presentation, prognosis and management of patients with glucagonoma.

Materials and methods: In this retrospective national cohort, diagnosis of glucagonoma was considered in patients with at least one major criterion (necrolytic migratory erythema (NME) and/or recent diabetes and/or significant weight loss) associated with either significant glucagonemia (>2xULN) or positive immunohistochemistry for glucagon. Antisecretory efficacy was defined as partial/complete improvement in NME. Antitumor efficacy was assessed by the time to next treatment (TTNT).

Conference:

Presenting Author:

Authors: Perrier M, Brugel M, Walter T, Goichot B, Lièvre A,

Keywords: glucagonoma, neuroendocrine neoplasm, pancreas, necrolytic migratory erythema,